NCT01991756Unknown不适用
ELEVATE International: Kissing Endografts for Peripheral AAA Exclusion
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 50
- 试验地点
- 4
- 主要终点
- Primary Safety Endpoint
研究概览
简要总结
The primary objective of the study is to evaluate the acute safety of deploying and implanting the Altura Endograft in the treatment of AAA in subjects who are candidates for endovascular repair.
Secondary objectives are to evaluate the acute and longer-term safety and performance of the Altura Endograft through 5 years.
详细描述
The primary safety endpoint of the study is freedom from Major Adverse Events (MAE), a composite endpoint consisting of death, stroke, paraplegia, myocardial infarction, respiratory failure, renal failure, bowel ischemia and blood loss ≥ 1000 mL.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years or older
- •Understands and has signed an Informed Consent
- •Candidate for endovascular or open surgical repair of an infrarenal aortic or aorto-iliac aneurysm
- •Abdominal aneurysm > 45 mm or aneurysm growth of > 10 mm/year
- •Abdominal aneurysm neck angulation ≤ 60 degrees
- •Infrarenal non-aneurysmal neck 15 mm
- •Infrarenal non-aneurysmal neck diameter between 18 and 28 mm, inclusive
- •Iliac artery landing zone 15 mm in length
- •Iliac artery landing zone diameter between 8 and 18 mm, inclusive
- •Patent iliac and femoral arteries, access vessels, size and morphology, to allow endovascular access of a minimum 14 Fr introducer sheath and catheter
- •Ability to preserve at least one hypogastric artery
- •Life expectancy > one year
- •American Society of Anesthesiology (ASA) grade 1 through 3, inclusive
- •Able and willing to comply with follow-up visits at 30 days, 6 and 12 months and annually through 5 years
排除标准
- •Pregnant or nursing
- •An acutely ruptured, leaking or emergent aneurysm
- •An aortic dissection (Type A or B)
- •A mycotic, infected or inflammatory aneurysm
- •A thoracic, suprarenal or juxtarenal aneurysm
- •Previous surgical or endovascular aneurysm repair for abdominal aortic aneurysm or an aorto-iliac aneurysm
- •Severe iliac artery tortuosity
- •Thrombus, calcification and/or plaque that may complicate sealing
- •Evidence or history of intracranial bleeding or aneurysm, myocardial infarction or stroke within the past 3 months
- •Current angina or other active cardiac condition such as congestive heart failure, untreated or worsening atrial arrhythmia, ventricular arrhythmia or valvular disease
- •Had or plans to have an unrelated major surgical or interventional procedure within 1 month before or after implantation of the study device
- •Significant (>80%) diameter renal artery stenosis which could not be readily treated
- •Known sensitivity or allergy to nitinol or polyester
- •Known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pre-treatment
- •Contraindication to antiplatelet, anticoagulant or thrombolytic therapy;
- •Coagulopathy or uncontrolled bleeding disorder
- •History of heparin-induced thrombocytopenia (HIT)
- •Clinically and morbidly obese such that the required imaging would be prevented
- •Connective tissue disease (e.g., Marfan's or Ehlers-Danlos syndromes)
- •Currently on dialysis or has compromised renal function as reflected by a serum creatinine >2.0 mg/dL
- •Compromised hepatic function
- •Active infection at the time of the index procedure
- •End-stage chronic obstructive pulmonary disorder (COPD)
- •Religious, cultural or other objections to the receipt of blood or blood products
- •Participating in another research study involving an investigational device or drug which may potentially affect study results
- •Other medical, social or psychological problems that, in the opinion of the Investigator, preclude them from receiving this treatment and the procedures and evaluations pre- and post-treatment
结局指标
主要结局
Primary Safety Endpoint
时间窗: 30 days
Freedom from Major Adverse Events (MAE), a composite endpoint consisting of: * Death * Stroke * Paraplegia * Myocardial infarction * Respiratory failure * Renal failure * Bowel ischemia * Blood loss ≥ 1000 mL
次要结局
- Secondary Safety Endpoint(30 days, 6 and 12 months and annually through 5 years)
研究者
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
1 期
An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes MellitusLong-standing Type 1 Diabetes MellitusNCT02064309Uppsala University Hospital4
Unknown
不适用
First in Man Study of Implantable Alginate HydrogelHeart FailureNCT04781660Xijing Hospital10
招募中
不适用
Feasibility Study to Evaluate an Intravascular Blood Continuous Glucose SensorDiabetes MellitusNCT06764069Glucotrack10
已完成
不适用
Performance and Safety of the ARGOS-SC Suprachoroidal Pressure Sensor in Patients With Glaucoma Undergoing Non-penetrating Glaucoma SurgeryGlaucomaOpen Angle GlaucomaNCT03756662Implandata Ophthalmic Products GmbH24
终止
不适用
Percutaneously Delivered Automated Continual Fluid Removal System in Patients With Advanced Diuretic-Resistant Heart FailureHeart FailureNCT06689553Paragate Medical LTD2